Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Services
2023 Readersâ Choice Winners
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biophytis Sa ADR
(NQ:
BPTS
)
0.3510
+0.0010 (+0.29%)
Streaming Delayed Price
Updated: 3:58 PM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Biophytis Sa ADR
< Previous
1
2
3
Next >
Biophytis: Results of the Combined General Meeting on April 17, 2023
April 18, 2023
Via
ACCESSWIRE
Biophytis: The Combined General Meeting Will Be Held on Second Call on April 17, 2023
March 30, 2023
Via
ACCESSWIRE
Biophytis: Biophytis Presented Sarconeos (BIO101) As A Possible Treatment Candidate for Long COVID After Hospitalization During The 13th Annual International Conference on Frailty and Sarcopenia Resea
March 27, 2023
Via
ACCESSWIRE
Biophytis Announces Ratio Change Under its American Depositary Receipt (“ADR”) Program
March 17, 2023
Via
ACCESSWIRE
Biophytis To Present Positive Results of Phase 2-3 COVA Study At ERS 2023 21st Lung Science Conference
March 09, 2023
Via
ACCESSWIRE
Biophytis Publishes its Financial Results for the First Half of 2022
January 31, 2023
Via
ACCESSWIRE
Biophytis: Judgment of the Paris Court of Appeal of 17 January 2023 in the Case Between Biophytis and Negma Group Ltd
January 19, 2023
Via
ACCESSWIRE
Biophytis Announces the Signature of a Master Service Agreement With Intsel Chimos, a Pharmaceutical Company That Will Operate Sarconeos (BIO101) in France for the Treatment of Severe Forms of COVID-19
March 02, 2023
Via
ACCESSWIRE
Biophytis Initiates the Regulatory Process for an Early Access Authorization in France from the French National Authority for Health (HAS) for the Treatment with Sarconeos (BIO101) of Severe Forms of COVID-19
February 27, 2023
Via
ACCESSWIRE
Biophytis To Host a Combined General Shareholder’s Meeting on March 30, 2023
February 23, 2023
Via
ACCESSWIRE
Biophytis Announces Positive Final Results of the Phase 2-3 COVA Study with Sarconeos (BIO101) in Severe COVID-19
February 02, 2023
Via
ACCESSWIRE
Biophytis To Take Appropriate Measures After Receiving Nasdaq Deficiency Notice
January 12, 2023
Via
ACCESSWIRE
Biophytis Announces Its Participation in Two Major Investor Conferences in January, In the United States and In France: The JP Morgan Healthcare Conference and The Invest Securities Biomed
January 05, 2023
Via
ACCESSWIRE
Biophytis Organises a Webcast with Key Opinion Leaders (KOL) On the Phase 2-3 Cova Study Results of Sarconeos (Bio101) In the Treatment of Pneumonia in Covid-19 Patients at Risk of Respiratory Failure
December 01, 2022
Via
ACCESSWIRE
Biophytis Reports Positive Post-hoc Analysis of The Phase 2-3 COVA Clinical Study Strongly Supporting Therapeutic Potential of Sarconeos (BIO101) In COVID-19
November 03, 2022
Via
ACCESSWIRE
Biophytis Publishes Its Key Financial Figures As at 30 June 2022, Announces a Restatement of the Financial Statements Published As of December 31st, 2021 and Provides an Update on the Operational Milestones
October 31, 2022
Via
ACCESSWIRE
Biophytis Announces Receipt of Nasdaq Notice
October 26, 2022
Via
ACCESSWIRE
Biophytis Participates in H.C. Wainwright 24th Annual Global Investment Conference
September 15, 2022
Via
ACCESSWIRE
The Paris Court of Appeal Rules in Favour of Biophytis in the Case Against Negma Group Ltd
September 13, 2022
Via
ACCESSWIRE
Biophytis Announces Very Promising Top Line Results of its Phase 2-3 COVA Clinical Study in COVID-19-Related Respiratory Failure
September 07, 2022
Via
ACCESSWIRE
Biophytis Announces the Drawing of the Second Tranche of Ornane Under the 2021 Atlas Contract for €4 Million
June 30, 2022
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 30, 2022 / Biophytis SA (NasdaqCM:BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of...
From
Biophytis
Via
AccessWire
Topics
Bonds
Exposures
Debt Markets
Biophytis Presents the Development of Sarconeos (BIO101) in Phase 3 for the Treatment of Sarcopenia at the 15th SCWD International Congress
June 27, 2022
PARIS, FRANCE and CAMBRIDGE, MASSACHUSETTS / ACCESSWIRE / June 27, 2022 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company...
From
Biophytis
Via
AccessWire
Biophytis: Results of the Combined General Meeting on June 21, 2022
June 22, 2022
All ordinary and extraordinary resolutions presented by the company have been adopted
From
Biophytis
Via
AccessWire
Biophytis: Convening of Another Combined General Meeting at a Later Date
June 03, 2022
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 3, 2022 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused on...
From
Biophytis
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
Biophytis: Biophytis Announces its Participation at the BIO International Convention in San Diego from the 13th to the 16th of June
May 12, 2022
PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / May 12, 2022 / Biophytis SA (NasdaqCM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused on...
From
Biophytis
Via
AccessWire
Exposures
COVID-19
Biophytis: Biophytis Presents Sarconeos (BIO101) Development Program in Sarcopenia at the 12th Annual International Conference on Frailty and Sarcopenia Research (ICFSR) in Boston April 20-22, 2022
April 19, 2022
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 19, 2022 / Biophytis SA ((NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused...
From
Biophytis
Via
AccessWire
Exposures
COVID-19
Biophytis Announces 2021 Operational and Financial Results and Gives Updates on 2022 perspectives
April 07, 2022
- Success of Nasdaq IPO in February 2021 - €23.9M of available cash on December 31 2021 and new financing instruments for a total of €42M allowing financial visibility beyond mid 2023 - Strong growth...
From
Biophytis
Via
AccessWire
Topics
Initial Public Offering
Exposures
COVID-19
Securities Market
Biophytis Provides Updates on Sarconeos (BIO101) Clinical Development
April 07, 2022
- Sarcopenia (SARA) : discussions engaged with FDA for the preparation of a Phase 2-3 program in sarcopenia, with the objective of having a First Patient In by end of H2 2022 - COVID-19 (COVA): 237...
From
Biophytis
Via
AccessWire
Exposures
COVID-19
Product Safety
Biophytis Appoints Philippe Rousseau as Chief Financial Officer
April 05, 2022
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 5, 2022 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company specialized...
From
Biophytis
Via
AccessWire
Biophytis will Participate in a Key Workshop on Functional Limitations for the Elderly
March 16, 2022
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / March 16,2022 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "company") a clinical-stage biotechnology company focused on...
From
Biophytis
Via
AccessWire
Exposures
COVID-19
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.